NCT07162480View on ClinicalTrials.gov

Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions
Adenoid Cystic Carcinoma
Interventions
DRUG

P-Sam

Given by IV

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER